Healthcare / BiotechnologyNasdaqCM
$19.72
-0.93 (-4.50%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-89.7M · quality 69.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$544M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-75.8%
↓Gross Margin
N/A
•Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2012–2025 · 13 años de histórico normalizado
Revenue CAGR
-2.6%
FCF CAGR
—
FCF margin
-1332.1%
FCF / Net income
0.94x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $10.8M · net income $-153.9M · FCF $-144.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||
| Revenue | $10.8M | $10.8M | — | — | — | — | — | — | — | — | $18500.00 | $20.1M | $15.0M | $4.0M | $15.3M |
| Net Income | $-153.9M | $-153.9M | — | $-36.9M | $-46.7M | $-63.4M | $-51.0M | $-57.9M | $-48.3M | $-33.3M | $-31.8M | $-12.8M | $-11.1M | $-10.6M | $3.7M |
| EBITDA | $-149.7M | $-149.7M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS | -12.81 | -12.81 | — | -58.00 | -89.00 | -123.00 | -112.00 | -134.00 | — | — | — | — | -60.00 | -887.00 | 33.00 |
| Operating Margin | -1407.5% | -1407.5% | — | — | — | — | — | — | — | — | -172505.3% | -63.7% | -74.1% | -265.7% | 23.8% |
| Net Margin | -1419.6% | -1419.6% | — | — | — | — | — | — | — | — | -171945.1% | -63.6% | -74.0% | -265.6% | 24.0% |
| Balance Sheet | |||||||||||||||
| Debt/Equity | 0.01 | 0.01 | -2.42 | — | — | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 13.78 | 13.78 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||
| Free Cash Flow | $-144.5M | $-144.5M | — | $-34.9M | $-46.5M | $-57.5M | $-39.3M | $-52.1M | $-43.5M | $-30.1M | $-30.4M | $-8.5M | — | — | — |
| Returns | |||||||||||||||
| ROE | -75.8% | -75.8% | — | -96.1% | -108.8% | -77.7% | -39.8% | -37.5% | -23.5% | -27.8% | -90.1% | -31.6% | -21.9% | -364.8% | 29.2% |
| Valuation | |||||||||||||||
| P/B | 1.01 | 1.01 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||
| Revenue Growth | — | — | — | — | — | — | — | — | — | — | -99.9% | 33.6% | 276.4% | -73.8% | — |
| EPS Growth | — | — | — | 34.8% | 27.6% | -9.8% | 16.4% | — | — | — | — | — | 93.2% | -2787.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-6.1%
Start / end P/E
n/dx → n/dx
EPS bridge
n/d → -12.81
Residual
-6.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.